Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/109389
Title: | Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis | Authors: | Coimbra, Susana Figueiredo, Américo Santos-Silva, Alice |
Keywords: | interleukin-17; interleukin-17 receptor; monoclonal antibody; T helper 17 pathway | Issue Date: | 2014 | Publisher: | Dove Medical Press Ltd | Serial title, monograph or event: | Core Evidence | Volume: | 9 | Abstract: | Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis. | URI: | https://hdl.handle.net/10316/109389 | ISSN: | 1555-1741 | DOI: | 10.2147/CE.S33940 | Rights: | openAccess |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Brodalumab-An-evidencebased-review-of-its-potential-in-the-treatment-of-moderatetosevere-psoriasisCore-Evidence.pdf | 465.07 kB | Adobe PDF | View/Open |
Page view(s)
61
checked on Oct 16, 2024
Download(s)
19
checked on Oct 16, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License